Fig. 1From: The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animalsPfCyRPA adjuvanted with either GLA-LSQ, GLA-SE, GLA-Alum or Nanoalum elicited in mice high IgG titers with in vitro parasite growth-inhibitory activity. ELISA readouts (optical density [OD] means ± standard deviations) obtained with serial dilution of mouse sera taken pre-immune and after each immunization are shown in a–e. Serum anti-PfCyRPA IgG ELISA endpoint titers of individual animals are shown in f–j and lines represent the mean titer. Determinations of IgG subclass profiles by ELISA using plates coated with recombinant PfCyRPA are shown in k–o. Sera from mice collected after the third immunization were tested individually at a serum dilution of 1:6400. Shown are OD values obtained with individual sera and means (colored bars). In vitro parasite growth-inhibitory activities of purified total IgG from pooled sera of each group of mice are shown in p–t. Dots represent duplicate replicates of two independent [3H]-hypoxanthine incorporation assays. For each group a four-parameter sigmoidal dose-response curve was fitted to the relationship between the log10 of the IgG concentration and percentage inhibition, and then used to interpolate IC50 valuesBack to article page